Brief: Oncolytics Biotech Announces Productive FDA Type C Meeting
27/06/2024 12:11
June 27 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ANNOUNCES PRODUCTIVE FDA TYPE C
MEETING ON
ITS METASTATIC BREAST CANCER PROGRAM
* ONCOLYTICS BIOTECH INC: ON TRACK TO REPORT OVERALL
SURVIVAL
RESULTS FROM RANDOMIZED HR+/HER2- METASTATIC BREAST CANCER
BRACELET-1 TRIAL IN H2 2024
Source text for Eikon: ID:nCNWrD94Ka
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer